Reviewer's report

**Title:** Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch

**Version:** 1 **Date:** 5 August 2010

**Reviewer:** Richard Bogan

**Reviewer's report:**

This article provides useful information in the longterm treatment of moderate to severe restless legs syndrome with rotigotine. The study design, conduct and analysis of the open label data appear accurate and useful clinically. It would be helpful to know the percentage of patients requiring significant dose increases from year 1 to year 2. Discussion of the SAE's considered treatment related in year 2 would be desirable.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

Dr. Richard Bogan has been a consultant to UCB, GSK and on the speakers bureau for GSK and Boehringer Ingelheim. He has participated in funded research trials sponsored by UCB/Schwarz Pharma, GSK, Pfizer, Boehringer Ingelheim and Xenoprot.